Benign Prostatic Hyperplasia: When Your Prostate Grows

The Organ That Never Stops Growing

The prostate is a walnut-sized gland that sits below the bladder and surrounds the urethra. Its primary function is producing prostatic fluid — a component of semen that nourishes and transports sperm. In most men, the prostate undergoes two growth phases: a doubling during puberty and a second, slower phase beginning around age 25 that continues for the rest of life.

This second growth phase eventually produces benign prostatic hyperplasia (BPH) — non-cancerous enlargement of the prostate — in the majority of men. Histological evidence of BPH is present in 50% of men by age 50 and 90% by age 80, according to a 2005 review in the New England Journal of Medicine. Not all men with histological BPH develop symptoms, but approximately 50% of men with measurable enlargement will experience clinically significant lower urinary tract symptoms (LUTS).

Why the Prostate Enlarges

The Hormonal Driver

BPH is driven primarily by dihydrotestosterone (DHT) — a metabolite of testosterone produced by the enzyme 5-alpha reductase within the prostate. DHT has 5x the binding affinity for the androgen receptor compared to testosterone and is the primary androgen responsible for prostate growth.

As men age, intraprostatic DHT levels remain relatively stable even as serum testosterone declines. A 2004 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that prostatic DHT concentrations in 80-year-old men were comparable to those in 30-year-old men, despite significantly lower circulating testosterone. This sustained DHT exposure drives continuous prostatic stromal and epithelial cell proliferation.

The Estrogen Connection

Aging men also experience a shift in the testosterone-to-estrogen ratio, with relative estrogen levels increasing. A 2008 review in The Prostate proposed that estrogen enhances the expression of androgen receptors in prostatic tissue, amplifying DHT's growth-promoting effects. This dual-hormone theory explains why BPH accelerates in older men despite declining testosterone.

Inflammatory Components

A 2017 study in Nature Reviews Urology identified chronic prostatic inflammation as a contributing factor in BPH progression. Inflammatory infiltrates (macrophages, T-lymphocytes) are found in 70-80% of BPH surgical specimens. These immune cells release cytokines and growth factors — including IL-6, IL-8, and FGF — that stimulate stromal proliferation independent of androgens.

Symptoms: The LUTS Spectrum

BPH symptoms fall into two categories:

Storage Symptoms (Irritative)

• Frequency: Urinating more than 8 times per day
• Urgency: Sudden, compelling need to urinate
• Nocturia: Waking to urinate 2+ times per night
• Urge incontinence: Involuntary leakage with urgency

Voiding Symptoms (Obstructive)

• Weak stream: Reduced force of urination
• Hesitancy: Difficulty initiating urination
• Intermittency: Stop-and-start urination
• Incomplete emptying: Sensation of residual urine
• Straining: Need to push to void
• Post-void dribbling: Continued dripping after urination

The International Prostate Symptom Score (IPSS) is a validated 7-question tool that quantifies LUTS severity on a 0-35 scale: mild (0-7), moderate (8-19), severe (20-35). The IPSS is used globally to guide treatment decisions and monitor response to therapy.

Diagnosis

Digital Rectal Examination (DRE)

The DRE allows the clinician to estimate prostate size, assess symmetry, and check for nodules suggestive of malignancy. A smooth, symmetrically enlarged gland is consistent with BPH. However, DRE is imprecise — it tends to underestimate prostate volume, particularly for larger glands.

PSA Testing

Prostate-specific antigen (PSA) is elevated in BPH proportional to gland volume: roughly 0.3 ng/mL per gram of BPH tissue, per a 1999 study in Urology. PSA testing helps differentiate BPH from prostate cancer, though overlap exists. A 2018 guideline from the American Urological Association recommends PSA testing as part of the BPH workup, with further evaluation for PSA values above 4.0 ng/mL or rapid PSA rises.

Uroflowmetry

This non-invasive test measures urinary flow rate. Peak flow rates below 10 mL/second suggest significant bladder outlet obstruction. Post-void residual volume measurement via ultrasound quantifies incomplete emptying.

Treatment Options

Watchful Waiting

For men with mild symptoms (IPSS 0-7) and no complications, observation with annual reassessment is appropriate. A 2003 randomized trial in the New England Journal of Medicine found that watchful waiting was safe for men with mild-to-moderate symptoms, with only 24% progressing to surgical treatment over 5 years.

Alpha-Blockers

Tamsulosin, alfuzosin, silodosin, and similar drugs relax smooth muscle in the prostate and bladder neck, reducing obstruction. They work within 1-2 weeks. A 2017 Cochrane review found alpha-blockers improved IPSS scores by an average of 4-6 points and peak flow rates by 2-3 mL/second.

Side effects: Dizziness, orthostatic hypotension, retrograde ejaculation (particularly with tamsulosin, occurring in 8-18% of users).

5-Alpha Reductase Inhibitors (5-ARIs)

Finasteride and dutasteride block DHT production, shrinking the prostate by 20-30% over 6-12 months. A 2010 meta-analysis in the Journal of Urology demonstrated that 5-ARIs reduced the risk of acute urinary retention by 57% and the need for surgery by 34% over 4 years.

Side effects: Decreased libido (5-8%), erectile dysfunction (5-7%), reduced ejaculate volume. These sexual side effects resolve upon discontinuation in most men, though a controversial entity called "post-finasteride syndrome" (persistent sexual dysfunction after stopping the drug) has been reported in case series.

Combination Therapy

The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial, published in the New England Journal of Medicine in 2003, demonstrated that combining an alpha-blocker with a 5-ARI reduced symptom progression by 66% compared to either agent alone — a synergistic effect that made combination therapy the standard of care for men with moderate-to-severe LUTS and enlarged prostates.

Surgical Options

When medical therapy fails or complications arise (recurrent urinary retention, recurrent UTIs, bladder stones, renal insufficiency), surgical intervention is indicated.

Transurethral resection of the prostate (TURP) remains the gold standard, removing obstructing prostate tissue through a resectoscope. A 2019 Cochrane review confirmed TURP produces a mean IPSS improvement of 15 points and peak flow improvement of 10 mL/second.

Newer minimally invasive options include:

• UroLift: Mechanical implants that retract obstructing prostate tissue; preserves sexual function
• Rezūm: Water vapor thermal therapy; office-based procedure under local anesthesia
• GreenLight laser: Photoselective vaporization; suitable for patients on anticoagulation
• Aquablation: Robotic waterjet ablation guided by real-time ultrasound

Lifestyle Modifications

Several non-pharmacological strategies reduce BPH symptoms:

• Fluid management: Reduce intake 2-3 hours before bedtime to minimize nocturia
• Caffeine and alcohol reduction: Both are bladder irritants that worsen frequency and urgency
• Double voiding: Urinating, waiting 30 seconds, then urinating again to empty the bladder more completely
• Physical activity: A 2008 prospective study in Medicine & Science in Sports & Exercise found that men exercising 3+ hours/week had a 25% lower risk of BPH surgery
• Weight management: Obesity increases BPH risk; each 1 kg/m² increase in BMI raises BPH risk by 3-5%, per a 2013 meta-analysis in European Urology

BPH is not prostate cancer and does not increase cancer risk. But it can significantly impair quality of life if left unmanaged. If you're waking twice a night to urinate or spending unreasonable time at the urinal, talk to your doctor — effective treatments exist across the entire severity spectrum.